Hospira Spins Off With $4.2 Bil. Market Cap; Abbokinase Stays With Abbott
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott initially pegged Abbokinase as one of its hospital-based products to be divested with Hospira, but later decided the drug had a more strategic fit with the rest of its Rx portfolio.
You may also be interested in...
Abbott Sells In Vitro, Point-Of-Care Diagnostics Businesses To General Electric For $8 Billion
Deal continues Abbott’s strategy over the last few years of becoming more focused on its pharmaceuticals business.
Abbott Sells In Vitro, Point-Of-Care Diagnostics Businesses To General Electric For $8 Billion
Deal continues Abbott’s strategy over the last few years of becoming more focused on its pharmaceuticals business.
Hospira's Precedex Phase IV Trial Postponed To 2005
The post-marketing safety study is being revised with FDA input. The sedative Precedex makes up only a small portion of Hospira's specialty injectables sales, which totaled $235 mil. in the U.S. for the third quarter.